Be the first person to write a business review for Metabolex, Inc.

MethylGene's endeavors in the field of medicine may earn it a good look. The company is developing enzyme inhibitors to treat cancer and various infectious diseases. It develops product candidates for treatments for ailments such as solid tumors and hematological malignancies. MethylGene has also researched therapies to battle conditions including fungal infections and antibiotic resistance. The company forms licensing and collaboration agreements with other pharmaceutical firms to further its development programs.

Genzyme and Medtronic are out to prove that it doesn't just take time to heal a broken heart. The two companies' joint venture, MG Biotherapeutics, was created in 2004 to develop new treatments for heart attacks and other cardiovascular conditions. The company in 2006 ceased enrollment of new patients in its Phase II clinical trial, which had been testing the use of cell therapy to repair damaged heart tissue following a heart attack, after evidence showed the trial would not be successful. MG Biotherapeutics is also engaged in long-term research into next-generation cell therapies and is developing a less-invasive, catheter-based delivery system for cell therapy using Medtronic's TransAccess technology.

Microbix makes biotherapeutic drugs, vaccines, and infectious disease diagnostics for multinational manufacturers. The company's pipeline includes leading generic drug candidate ThromboClear for the treatment of coronary artery thrombosis and the FDA-approved drug urokinase, used to treat pulmonary embolism. Microbix has also submitted patents for its Sperm Sexing Technology, which enables livestock producers to predetermine offspring gender prior to conception. In 2008 Microbix entered into an agreement with China to build one of the world's largest influenza manufacturing plants to produce flu vaccines.

MicroIslet, Inc. is a biotechnology company engaged in the research, development and commercialization of technologies in the field of transplantation therapy for people with conditions requiring cell-based replacement treatments, with a focus on type 1, or insulin-dependent diabetes. Islet transplantation technology, licensed from Duke University, along with the Company's developments, constitutes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet intends to continue its research and development efforts and to introduce products to the market.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company’s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.